
Apop’s breakthrough CalRexin® technologies are transforming our knowledge of complex cell stress mechanisms associated with programmed cell death (PCD) and autophagy which are important for several significant diseases. We have launched a pipeline of proprietary novel imaging reagents to interrogate these mechanisms, to be followed by a range of emerging therapeutics and diagnostics products. All Apop products are based on our proprietary calcitonin receptor antibody technology, CalRexin®, that targets a novel extracellular marker of these complex processes, is accumulated into live stressed…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.